Venmax Drugs & Pharmaceuticals Ltd

Venmax Drugs has experienced significant fluctuations in financial performance, with net sales increasing to 0.81 Cr in March 2025 from 0.00 Cr in the previous year, but overall profitability declined, resulting in a negative profit after tax of -0.01 Cr. Despite growth in sales and total assets, the company faces challenges in maintaining profitability due to rising expenditures and liabilities.

As of 03-Nov, Venmax Drugs & Pharmaceuticals Ltd is experiencing a price increase to 28.70, with a recent gain of 10.09% over three days and a 42.43% rise in the past month, outperforming the Sensex. However, a significant decline in delivery volume by 77.96% raises concerns about sustained investor interest.

As of 28-Oct, Venmax Drugs & Pharmaceuticals Ltd is priced at 27.88, down 1.31%. Despite recent declines, the stock has shown strong monthly and year-to-date performance, but its short-term drop contrasts with overall positive trends and outperformance against the Sensex.

As of 24-Oct, Venmax Drugs & Pharmaceuticals Ltd is experiencing a price increase to Rs 29.71, up 4.61%, with strong performance over the past nine days and significant outperformance compared to the Sensex. The stock is trending bullish, supported by increased delivery volume and a notable rise in returns both short-term and year-to-date.

As of 17-Oct, Venmax Drugs & Pharmaceuticals Ltd is seeing a price increase to Rs 25.44, up 4.99%, with strong weekly and monthly gains. Despite a significant drop in investor participation, the stock has outperformed the Sensex, indicating positive sentiment.

As of 15-Oct, Venmax Drugs & Pharmaceuticals Ltd is experiencing a price increase to Rs 23.08, up 4.96%, with strong short-term performance but an 11.40% decline over the past month and decreased investor participation. The stock has outperformed the Sensex significantly year-to-date, indicating resilience despite mixed long-term signals.

As of 13-Oct, Venmax Drugs & Pharmaceuticals Ltd is currently priced at 20.95, reflecting a 4.96% increase and significant investor interest with a 119.92% rise in delivery volume. Despite recent volatility, the stock has outperformed the Sensex year-to-date, indicating a recovery phase and improved trading activity.

As of 06-Oct, Venmax Drugs & Pharmaceuticals Ltd is facing a stock price decline to 19.22, down 4.62%, and has underperformed significantly against the Sensex, with a 22.19% drop in the last month. The stock is trading below all key moving averages and has seen a substantial decrease in delivery volume, indicating a bearish trend and reduced investor interest.

As of 26-Sep, Venmax Drugs & Pharmaceuticals Ltd's stock price is Rs 22.10, down 4.91%, and has declined 7.57% over the last two days. The stock has significantly underperformed its sector and the broader market, with steep declines over the past week and month, indicating a challenging period for the company.

As of 24-Sep, Venmax Drugs & Pharmaceuticals Ltd is priced at 23.91, showing a slight increase but trading below all key moving averages, indicating a bearish trend. The stock has outperformed its sector today, but has underperformed the benchmark Sensex in the short term, with a significant decline over the past month.

As of 23-Sep, Venmax Drugs & Pharmaceuticals Ltd's stock price is Rs 23.85, down 4.98%, and has declined 9.66% over the last two days. The stock is underperforming its sector and the Sensex, with significantly reduced investor participation, indicating a bearish trend.

As of 22-Sep, Venmax Drugs & Pharmaceuticals Ltd's stock price is Rs 25.10, down 4.92%, and has underperformed its sector. Despite a year-to-date gain of 39.14%, recent trends indicate a decline in value and investor sentiment.

As of 19-Sep, Venmax Drugs & Pharmaceuticals Ltd is currently priced at Rs 26.40, reflecting a recent increase but has underperformed over the past week and month. Despite a year-to-date gain of 46.34%, declining investor participation raises concerns about the stock's sustained interest.

As of 18-Sep, Venmax Drugs & Pharmaceuticals Ltd is currently priced at Rs 25.25, reflecting a 4.99% increase today after three days of decline. Despite this short-term rebound, the stock has underperformed over the past week and month, with significant drops in investor participation.

As of 17-Sep, Venmax Drugs & Pharmaceuticals Ltd is priced at 24.05, having declined 2.91% over the last three days, totaling a drop of 12.1%. The stock is trading below all major moving averages and has significantly underperformed compared to the Sensex, which has risen while Venmax has seen a 15.64% decline over the past month.

As of 16-September, Venmax Drugs & Pharmaceuticals Ltd's stock price is Rs 24.77, down 4.91%, and has underperformed its sector by 5.19% today. Despite a strong year-to-date return of 37.31%, recent trends indicate a decline in both short-term performance and investor participation.

As of 15-Sep, Venmax Drugs & Pharmaceuticals Ltd's stock price is Rs 26.05, down 4.79%, underperforming its sector and showing decreased investor participation. Despite a strong year-to-date return of 44.40%, recent volatility and a decline over the past month highlight specific challenges for the company.

As of 10-Sep, Venmax Drugs & Pharmaceuticals Ltd's stock price is Rs 24.00, down 4.76%, with a significant decline of 12.28% over the past week and 17.72% over the past month, despite a year-to-date increase of 33.04%. The stock is experiencing mixed signals, trading above its 200-day moving average but below shorter-term averages, while investor participation has notably increased despite the price drop.

As of 09-Sep, Venmax Drugs & Pharmaceuticals Ltd is currently priced at Rs 25.20, showing a 5.0% increase today after eight days of decline, but it has experienced significant volatility and a 12.47% drop over the past week. Despite a strong year-to-date return of 39.69%, decreased investor participation and recent declines indicate challenges diverging from broader market trends.